

I. Requirements for Prior Authorization of Neuropathic Pain Agents

A. Prescriptions That Require Prior Authorization

Prescriptions for Neuropathic Pain Agents that meet any of the following conditions must be prior authorized:

1. A non-preferred Neuropathic Pain Agent. See the Preferred Drug List (PDL) for the list of preferred Neuropathic Pain Agents at: <https://papdl.com/preferred-drug-list>.
2. A prescription for a gabapentinoid when there is a record of a recent paid claim for another gabapentinoid (therapeutic duplication).

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Neuropathic Pain Agent, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. Is being treated for a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication; **AND**
2. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
3. For Gralise (gabapentin extended-release), has a history of therapeutic failure, contraindication, or intolerance to **both** of the following:
 - a. Tricyclic antidepressants
 - b. Regular-release gabapentin (titrated to maximal tolerated effective dose of 1800 mg/day);

AND

4. For Horizant (gabapentin enacarbil), **one** of the following:
 - a. For a diagnosis of postherpetic neuralgia, has a documented history of therapeutic failure, intolerance, or contraindication to **both** of the following:
 - i. Tricyclic antidepressants
 - ii. Regular-release gabapentin (titrated to maximal tolerated effective dose of 1800 mg/day)
 - b. For a diagnosis of moderate-to-severe primary restless leg syndrome, has a documented history of therapeutic failure, intolerance, or contraindication to **both** of the following:
 - i. Regular-release gabapentin (titrated to maximal tolerated effective dose of 1800 mg/day)
 - ii. **One** of the following:
 - a) Pramipexole
 - b) Ropinirole;

AND

5. For all other non-preferred Neuropathic Pain Agents, has a history of therapeutic failure, contraindication, or intolerance of the preferred Neuropathic Pain Agents approved or medically accepted for the beneficiary's diagnosis; **AND**
6. For a Neuropathic Pain Agent that is subject to the U.S. Drug Enforcement Agency (DEA) Controlled Substances Act (i.e., controlled substance), has documentation that the prescriber or the prescriber's delegate conducted a search of the Pennsylvania Prescription Drug Monitoring Program (PDMP) for the beneficiary's controlled substance prescription history; **AND**
7. For therapeutic duplication of a gabapentinoid, **one** of the following:
 - a. Is being titrated to or tapered from another gabapentinoid
 - b. Has a medical reason for concomitant use of the requested medications that is supported by peer-reviewed literature or national treatment guidelines;

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

FOR RENEWALS OF PRIOR AUTHORIZATION FOR NEUROPATHIC PAIN AGENTS: The determination of medical necessity of a request for renewal of a prior authorization for a Neuropathic Pain Agent that was previously approved will take into account whether the beneficiary:

1. Has documentation of tolerability and a positive clinical response to the medication; **AND**
2. For a Neuropathic Pain Agent that is subject to the DEA Controlled Substances Act (i.e., controlled substance), has documentation that the prescriber or the prescriber's delegate conducted a search of the PDMP for the beneficiary's controlled substance prescription history

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Neuropathic Pain Agent. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

NON-PREFERRED MEDICATION PRIOR AUTHORIZATION FORM (form effective 01/01/20)

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		# of pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:			NPI:	State license #:
LTC facility contact/phone:			Street address:	
Beneficiary name:			Suite #:	City/State/Zip:
Beneficiary ID#:	DOB:	Phone:	Fax:	
Medication will be billed via: <input type="checkbox"/> Pharmacy <input type="checkbox"/> Medical (Jcode: _____)			Place of Service: <input type="checkbox"/> Hospital <input type="checkbox"/> Provider's Office <input type="checkbox"/> Home <input type="checkbox"/> Other	

Please refer to <https://papdl.com/preferred-drug-list> for the list of preferred and non-preferred medications in each Preferred Drug List class.

Non-preferred medication name:		Dosage form:	Strength:
Directions:		Quantity:	Refills:
Diagnosis (submit documentation):		DX code (required):	
Has the beneficiary taken the requested non-preferred medication in the past 90 days? (submit documentation)..... <input type="checkbox"/> Yes <input type="checkbox"/> No			
Describe all applicable medical reasons the beneficiary cannot use the preferred medication(s) in the same Preferred Drug List class. Submit documentation (e.g., recent chart/clinic notes, diagnostic evaluations, lab results, etc.) supporting this non-preferred request.			
<input type="checkbox"/> Treatment failure or inadequate response with preferred medication(s) (include drug name, dose, and start/stop dates): _____ _____			
<input type="checkbox"/> Unacceptable side effects, hypersensitivities, or other intolerances to preferred medication(s) (include description and drug name(s)): _____ _____			
<input type="checkbox"/> Contraindication to preferred medication(s) (include description and drug name(s)): _____ _____			
<input type="checkbox"/> Unique clinical or age-specific indications supported by FDA approval or medical literature (describe): _____ _____			
<input type="checkbox"/> Absence of preferred medication(s) with appropriate formulation (list medical reason formulation is required): _____ _____			
<input type="checkbox"/> Drug-drug interaction with preferred medication(s) (describe): _____ _____			
<input type="checkbox"/> Other medical reason(s) the beneficiary cannot use the preferred medication(s) (describe): _____ _____			
<input type="checkbox"/> For renewal requests of previously approved medications, submit documentation of tolerability and beneficiary's clinical response.			

PLEASE FAX COMPLETED FORM TO GATEWAY – PHARMACY DIVISION

Prescriber Signature:	Date:
------------------------------	--------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.